Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 4;18(1):955.
doi: 10.1186/s12885-018-4860-1.

Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients

Damien Botsen  1 , Marie-Amélie Ordan  2 , Coralie Barbe  3 , Camille Mazza  2 , Marine Perrier  2 , Johanna Moreau  2   4 , Mathilde Brasseur  2   4 , Yohann Renard  5 , Barbara Taillière  6 , Florian Slimano  2 , Eric Bertin  7 , Olivier Bouché  2   4
Affiliations

Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients

Damien Botsen et al. BMC Cancer. .

Abstract

Background: FIGHTDIGO study showed the feasibility and acceptability of handgrip strength (HGS) measure in routine in 201 consecutive patients with digestive cancer treated with ambulatory chemotherapy. The present study focuses on the second aim of FIGHTDIGO study: the relationships between pre-therapeutic dynapenia and chemotherapy-induced Dose-Limiting Toxicities (DLT).

Methods: In this ancillary prospective study, DLT were analyzed in a sub-group of 45 chemotherapy-naive patients. Two bilateral consecutive measures of HGS were performed with a Jamar dynamometer before the first cycle of chemotherapy. Dynapenia was defined as HGS < 30 kg (men) and < 20 kg (women). DLT and/or Dose-Limiting Neurotoxicity (DLN) were defined as any toxicity leading to dose reduction, treatment delays or permanent treatment discontinuation.

Results: Two-thirds of chemotherapies were potentially neurotoxic (n = 31 [68.7%]) and 22 patients (48.9%) received FOLFOX (5FU, leucovorin plus oxaliplatin) regimen chemotherapy. Eleven patients (24.4%) had pre-therapeutic dynapenia. The median number of chemotherapy cycles was 10 with a median follow-up of 167 days. Twenty-two patients experienced DLT (48.9%). There was no significant association between pre-therapeutic dynapenia and DLT (p = 0.62). Nineteen patients (42.2%) experienced DLN. In multivariate analysis, dynapenia and tumoral location (stomach, biliary tract or small intestine) were independent risk factors for DLN (HR = 3.5 [1.3; 9.8]; p = 0.02 and HR = 3.6 [1.3; 10.0]; p = 0.01, respectively).

Conclusions: Digestive cancer patients with pre-therapeutic dynapenia seemed to experience more DLN. HGS routine measurement may be a way to screen patients with frailty marker (dynapenia) who would require chemotherapy dose adjustment and adapted physical activity programs.

Trial registration: NCT02797197 June 13, 2016 retrospectively registered.

Keywords: Antineoplastic agents; Digestive system neoplasms; Dose-limiting toxicity; Dynapenia; Muscle strength; Sarcopenia.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Informed written consent was obtained for each enrolled patient in the trial. The FIGHTDIGO study was approved by the ethics committee (Committee for the Protection of Person EST I DIJON, 25 March 2016) and was registered in Clinicaltrials.gov (NCT02797197).

Consent for publication

none

Competing interests

Damien Botsen reports personal fees from Pierre Fabre and non-financial support from GlaxoSmithKline, Novartis, Chugai, and Amgen outside the submitted work.

Camille Mazza reports personal fees from Pierre Fabre outside the submitted work.

Mathilde Brasseur reports personal fees from Bayer and non-financial support from Pierre Fabre, Novartis, Amgen, Roche, and AbbVie outside the submitted work.

Olivier Bouche reports grants from Roche, personal fees from Roche, grants from Pierre Fabre, personal fees from Pierre Fabre, personal fees from Amgen, personal fees from Bayer, personal fees from Lilly, personal fees from Merck, personal fees from Novartis, outside the submitted work.

Yohann Renard reports grants from Bard and Allergan, outside the submitted work. Marie-Amélie Ordan, Marine Perrier, Johanna Moreau, Coralie Barbe, Florian Slimano, Barbara Taillière, Eric Bertin: The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Association between dynapenia and Dose-Limiting Neurotoxicity (DLN). p = 0.002. Hazard Ratio = 3.5 [1.3; 9.8]
See this image and copyright information in PMC

References

    1. World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 5 Feb 2017.
    1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495. doi: 10.1016/S1470-2045(10)70218-7. - DOI - PubMed
    1. Manini TM, Clark BC. Dynapenia and aging: an update. J Gerontol A Biol Sci Med Sci. 2012;67(1):28–40. doi: 10.1093/gerona/glr010. - DOI - PMC - PubMed
    1. Evans WJ, Campbell WW. Sarcopenia and age-related changes in body composition and functional capacity. J Nutr. 1993;123(2 Suppl):465–468. doi: 10.1093/jn/123.suppl_2.465. - DOI - PubMed
    1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing. 2010;39(4):412–423. doi: 10.1093/ageing/afq034. - DOI - PMC - PubMed

Substances

Associated data